Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: A randomized trial

Calcified Tissue International

Volumn 61, Issue 4, 1997, Pages 266-271

  Boutsen, Y ^a   Jamart, J ^a   Esselinckx, W ^a   Stoffel, M ^a   Devogelaer, J P ^b  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Bisphosphonates; Bone mineral density; Glucocorticoids; Osteoporosis; Pamidronate

Indexed keywords

PAMIDRONIC ACID; PREDNISOLONE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERALIZATION; CALCIUM INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LONG TERM CARE; LUMBAR SPINE; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATIC DISEASE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; BONE DENSITY; CALCIUM; DENSITOMETRY, X-RAY; DIPHOSPHONATES; FEMALE; FEMUR; HUMANS; INJECTIONS, INTRAVENOUS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PREDNISOLONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0030931764     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002239900334     Document Type: Article

References (39)

1. Lukert BP, Raisz LG (1990) Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112: 352-364
2. Sambrook PN, Jones G (1995) Corticosteroid osteoporosis. Br J Rheumatol 34:8-12
3. Adachi JD, Bensen WG, Hodsman AB (1993) Corticosteroid-induced osteoporosis. Semin Arthritis Rheum 22:375-384
4. Adinoff Ad, Hollister JR (1983) Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 309:265-268
5. Cooper C, Barker DJP, Wickham C (1988) Physical activity, muscle strength, and calcium intake in fracture of the proximal femur in Britain. Br Med J 297:1443-1446
6. Reid IR, Ibbertson HK (1986) Calcium supplements in the prevention of steroid-induced osteoporosis. Am J Clin Nutr 44:287-290
7. Devogelaer JP, Esselinckx W, Nagant de Deuxchaisnes C (1994) Calcidiol protects bone mass in rheumatoid arthritis patients treated by low dose glucocorticoids. In: Norman AW, Bouillon R, Thomasset M (eds) Vitamin D, a pluripotent steroid hormone: structural studies, molecular endocrinology and clinical applications. W de Gruyter, Berlin, New York pp 855-856
8. Ringe JD, Welzel D (1987) Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 33: 35-39
9. Lukert BP, Johnson BE, Robinson RG (1992) Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 7:1063-1069
10. Reid IR, Wattie DJ, Evans MC, Stapleton JP (1996) Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 156:1133-1134
11. Guaydier-Souquières G, Kotzki PO, Sabatier JP, et al (1996) In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study. Osteoporosis Int 6:171-177
12. Worth H, Stammen D, Keck E (1994) Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate. Am J Respir Crit Care Med 150:394-397
13. Adachi JD, Cranney A, Goldsmith CH, et al (1994) Intermittent cyclic therapy with etidronate in the prevention of corticosteroid-induced bone loss. J Rheumatol 21:1922-1926
14. Skingle SJ, Crisp AJ (1994) Increased bone density in patients on steroids with etidronate. Lancet 344:543-544
15. Mulder H, Struys A (1994) Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheum 33:348-350
16. Diamond T, McGuigan L, Barbagallo S, et al (1995) Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 98:459-463
17. Struys A, Snelder AA, Mulder H (1995) Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 99:235-242
18. Puolijoki H, Herrala J, Liippo K, et al (1994) Clodronate in the treatment of corticosteroid-induced osteoporosis among asthmatic patients. Bone Miner 25 (suppl 1):575
19. Reid IR, King AR, Alexander CJ, et al (1988) Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet i:143-146
20. Reid IR, Heap SW, King AR, Ibbertson HK (1988) Two-year follow-up of biphosphonate (APD) treatment in steroid osteoporosis. Lancet ii:1144
21. Gallacher SJ, Kathryn Fenner JA, Anderson, K, et al (1992) Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid-dependent lung disease: an open pilot study. Thorax 47:932-936
22. Falcini F, Trapani S, Ermini M, Brandi ML (1996) Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling. Calcif Tissue Int 58:166-169
23. Eastell R, Devogelaer JP, Peel NFA, et al (1996) A double-blind, placebo-controlled study to determine the effects of risedronate on bone loss in glucocorticoid-treated rheumatoid arthritis patients. Osteoporosis Int 6 (suppl 1):96
24. Devogelaer JP, Huaux JP, Esselinckx W, et al (1987) Bone-sparing action of deflazacort versus equipotent doses of prednisone: a double-blind study in males with rheumatoid arthritis. In, Christiansen C, Johansen JS, Riis BJ (eds) Osteoporosis 2. Osteopress, Denmark, pp 1014-1015
25. Eastell R (1995) Management of corticosteroid-induced osteoporosis. J Int Med 237:439-447
26. Gennari C, Civitelli R (1986) Glucocorticoid-induced osteoporosis. Clin Rheum Dis 12:637-654
27. LoCascio V, Bonucci E, Imbimbo B, et al (1990) Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8: 39-51
28. Julian BA, Laskow DA, Dubovsky J, et al (1991) Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 325:544-550
29. Laan RF, van Riel PL, van de Putte LB, et al (1993) Low-dose prednisolone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Intern Med. 119:963-968
30. Papapoulos SE (1993) The role of bisphosphonates in the prevention and treatment of osteoporosis. Am J Med 95(suppl 5A):48-51
31. Pocock SJ, Simon R (1975) Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115 (correction: 1976;32:954-955)
32. Devogelaer JP, Baudoux C, Nagant de Deuxchaisnes C (1992) Reproducibility of BMD measurements on the Hologic QDR-2000 In: Ring EFJ (eds) Current research in osteoporosis and bone mineral measurement. British Institute of Radiology, London
33. Minne HW, Leidig G, Wuster C, et al (1988) A newly developed spine deformity index (SDI) to quantitiate vertebral crush fractures in patients with osteoporosis. Bone Miner 3: 335-349
34. Liang KY, Zeger SL (1986) Longitudinal data analysis using generalized linear models. Biometrika 73:13-22
35. Davis CS (1993) A computer program for regression analysis of repeated measures using generalized estimating equations. Comput Methods Programs Biomed 40:15-31
36. Eggelmeijer F, Papapoulos SE, van Paassen HC, et al (1996) Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum 39(3):396-402
37. Devogelaer JP, Nagant de Deuxchaisnes C (1990) Treatment of involutional osteoporosis with the bisphosphonate APD (disodium pamidronate): non-linear increase of lumbar bone mineral density. In: Christiansen C, Overgaard K (eds) Osteoporosis 1990. Handelstrykkeriet Aalborg Aps, pp 1507-1509
38. Heaney RP (1995) Interpreting trials of bone-active agents. Am J Med 98:329-330
39. Buckley LM, Leib ES, Cartularo KS, et al (1995) Effects of low dose corticosteroids on the bone mineral density of patients with RA. J Rheumatol 22:1055-1059